Clinical efficacy, drug sustainability and serum drug levels in Crohn's disease patients treated with ustekinumab – A prospective, multicenter cohort from Hungary

Hasonló tételek

• Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn’s disease patients over three years
  Szerző: Barkai László József, et al.
  Megjelent: (2024)
• Ustekinumab is associated with superior treatment persistence but not with higher remission rates versus vedolizumab in patients with refractory Crohn’s disease results from a multicentre cohort study /
  Szerző: Bacsur Péter, et al.
  Megjelent: (2022)
• Anti-TNF dose escalation and drug sustainability in Crohn's disease Data from the nationwide administrative database in Hungary /
  Szerző: Kósa Fruzsina, et al.
  Megjelent: (2020)
• Antiarrhythmic drugs limited effectiveness and proarrhythmia /
  Szerző: Farkas András
  Megjelent: (2002)
• Endoscopic Postoperative Recurrence In Crohn's Disease After Curative Ileocecal Resection With Early Prophylaxis By Anti-Tnf, Vedolizumab Or Ustekinumab A Real-World Multicenter European Study /
  Szerző: Yanai Henit, et al.
  Megjelent: (2022)